Table 2. Median overall survival for different subgroups.

Subgroups	SCP, months (95% CI)	CSP, months (95% CI)	P
Entire cohort	3 (2, 5)	8 (4, 9)	0.562
Age, years
<70	3 (3, 5)	8 (2, 16)	0.244
≥70	5 (2, 8)	5 (3, 8)	0.617
Sex
Female	3 (2, 6)	6 (3, 12)	0.840
Male	3 (2, 8)	8 (4, 11)	0.500
Race
White	3 (2, 8)	8 (4, 11)	0.784
Black	2 (1, 5)	2 (2, –)	0.979
Asian/Pacific Islander	5 (1, –)	4 (4, –)	0.501
Year of diagnosis
2000–2009	3 (2, 10)	6 (3, 11)	0.858
2010–2016	3 (2, 6)	8 (4, 16)	0.413
Primary site
Head	3 (2, 6)	8 (3, 28)	0.624
Body/tail	5 (2, 6)	5 (3, 11)	0.985
Other¶	3 (2, 10)	6 (1, –)	0.761
Tumor size*
<6 cm	3 (2, 8)	6 (4, 8)	0.885
≥6 cm	3 (2, 5)	8 (2, 13)	0.305
SEER stage#
Localized	16 (2, –)	11 (3, –)	0.844
Regional	9 (2, 60)	9 (6, 16)	0.501
Distant	2 (2, 3)	3 (1, 5)	0.936
CDS
Yes	10 (6, –)	8 (6, 12)	0.115
No	2 (2, 3)	2 (1, –)	0.254
Chemotherapy
Yes	5 (3, 8)	9 (6, 13)	0.102
No/unknown	2 (1, 6)	4 (2, 6)	0.586
Radiation
Yes	5 (2, –)	6 (6, –)	0.622
No/unknown	3 (2, 6)	8 (3, 9)	0.628

^¶, including other specified parts of pancreas (Code of the International Classification of Oncology, third edition: C257), Overlapping lesion of pancreas (C258), and Pancreas, NOS (C259). *, exact data available for 74 cases of SCP and 28 cases of CSP; ^#, data not available for 8 cases who were diagnosed in 2016. SCP, sarcomatoid carcinoma of the pancreas; CSP, carcinosarcoma of the pancreas; CI, confidence interval; SEER, Surveillance Epidemiology and End Results; CDS, cancer-directed surgery.